By Jonathan Gardner | September 21, 2026
In a pivotal "capital markets day" held in London this week, Novo Nordisk executives laid out an ambitious, multi-pronged roadmap designed to reset the company’s trajectory. As the pharmaceutical giant navigates a bruising competitive landscape, the primary objective is clear: to bridge the gap with its chief rival, Eli Lilly, and restore its position as the undisputed leader in the multibillion-dollar obesity drug market. Under the stewardship of new CEO Mike Doustdar, the company is betting on a combination of aggressive research partnerships, artificial intelligence integration, and a refined pipeline to recapture investor confidence.
The Core Challenge: The Rise of Eli Lilly
Novo Nordisk once defined the modern era of metabolic care. Twelve years ago, the company pioneered the GLP-1 space with the approval of liraglutide—marketed as Saxenda—for weight loss. For years, the company enjoyed a first-mover advantage, setting the standard for how the industry approached obesity.
However, the landscape has shifted seismically. Eli Lilly, buoyed by the runaway success of its dual-acting GLP-1/GIP receptor agonist, has fundamentally altered the competitive math. Marketed as Mounjaro for diabetes and Zepbound for chronic weight management, Lilly’s platform has demonstrated efficacy profiles that have consistently challenged Novo’s flagship Wegovy.
The rivalry has moved beyond the laboratory and into the courtroom and the public square. Novo has frequently contested claims regarding the comparative superiority of Zepbound, yet trial data—specifically regarding the absolute magnitude of weight loss—has consistently kept pressure on Novo’s stock and market share. The competitive friction is perhaps most evident in the ongoing tug-of-war over clinical trial results, where both firms scramble to prove their molecule offers the best outcomes for patients.
Chronology: A Decade of Disruption and Adaptation
- 2014: Novo Nordisk receives FDA approval for Saxenda, marking the dawn of the modern GLP-1 weight-loss era.
- 2021: Wegovy is approved, becoming a global sensation and triggering an unprecedented demand cycle that forces the company to grapple with supply chain constraints.
- 2023–2024: Eli Lilly’s Zepbound gains momentum, with clinical data showing strong performance against Wegovy. Market skepticism grows regarding Novo’s long-term dominance.
- 2025: Novo experiences a series of setbacks, including a disappointing performance for its oral GLP-1 pill and increased pressure from Lilly’s competing pill, Foundayo.
- Mid-2026: Novo undergoes a major leadership shakeup, appointing Mike Doustdar as CEO. The company initiates a massive restructuring, including the layoff of 9,000 employees and a complete overhaul of its board of directors.
- September 2026: The London Capital Markets Day signals a new strategic focus, emphasizing AI-driven discovery and a pivot toward next-generation oral therapeutics.
Supporting Data: The Battle of the Pipelines
The recent trial results for CagriSema serve as a microcosm of the current conflict. Novo Nordisk recently highlighted data suggesting that its experimental candidate, CagriSema, demonstrated superiority over Zepbound. However, critics and market analysts were quick to note that the trial compared the highest doses of CagriSema against the second-lowest dose of Lilly’s medication, sparking a debate over the clinical utility of the comparison.
This "data war" is compounded by the struggles of Novo’s oral programs. While Novo hoped to capitalize on its first-to-market advantage with an oral version of semaglutide, the launch failed to meet Wall Street’s aggressive growth projections. When Lilly followed with the approval of Foundayo, it effectively neutralized what was meant to be a defensive wall for Novo’s franchise.
Furthermore, the company’s R&D efforts have faced headwinds in non-obesity sectors. A highly anticipated Phase 3 trial for ziltivekimab, a drug intended to treat heart disease, failed to deliver the breakthrough results investors were banking on, further narrowing the company’s near-term growth narrative.
The Strategic Pivot: AI and Acquisitions
Recognizing that internal development alone may not be enough to outpace Lilly, Novo has radically changed its approach to R&D. In the weeks leading up to the London presentation, the company announced a flurry of tactical maneuvers:
- AI-Driven Discovery: A headline partnership with AI specialist Anthropic aims to accelerate the discovery and development cycle, potentially shaving years off the time required to bring novel molecules to the clinic.
- External Innovation: Novo has partnered with Orbis Medicines to leverage macrocyclic peptide technology, an effort to create more potent, shelf-stable oral drugs that could solve the bioavailability issues plaguing earlier versions of their GLP-1 pills.
- Targeted Acquisitions: By acquiring a trio of obesity drug prospects from Kallyope, Novo is effectively diversifying its portfolio beyond the standard GLP-1 mechanism, seeking the "next big thing" in metabolic regulation.
Official Responses and Corporate Restructuring
The installation of Mike Doustdar as CEO represents more than just a change in personnel; it is a signal of a leaner, more aggressive corporate culture. The layoff of 9,000 employees, while painful, is part of a broader "streamlining" effort intended to free up capital for R&D and commercial infrastructure.
During the London presentation, executives were candid about the hurdles ahead. They acknowledged the "patent cliff" looming in 2032, when the U.S. patent for semaglutide is set to expire. To offset this, the company is projecting that its sales growth will remain "in line" with industry peers through 2030, a modest target that reflects the reality of a saturated, highly competitive market.
"We are not looking to just defend our past," a company spokesperson noted during the Q&A session. "We are building a portfolio that accounts for the reality that the market has evolved. We are moving from the era of the first GLP-1s into an era of precision metabolic medicine."
Implications: What Lies Ahead for Investors and Patients
For the healthcare sector, the implications of Novo’s struggle are profound. The battle between Novo and Lilly is essentially a multi-billion dollar arms race that has accelerated the pace of medical innovation. Patients are the primary beneficiaries, as they now have access to a variety of treatment modalities, from weekly injections to daily pills.
However, for investors, the outlook remains cautious. With the majority of Novo’s pipeline currently in Phase 2 development or earlier, the company is in a precarious "bridge" period. It must maintain the dominance of Wegovy while simultaneously proving that its next-generation assets can succeed where its current ones have faltered.
The company’s decision to rebrand and lean heavily into AI and external partnerships suggests that the "old" Novo Nordisk—a firm that relied on slow, steady, and internal development—is gone. The "new" Novo is a company in a hurry, forced to innovate at breakneck speed to satisfy both shareholders and a patient population that no longer views weight loss drugs as a novelty, but as a standard of care.
As the industry looks toward the 2027 fiscal year, all eyes will be on whether the Kallyope assets and the Anthropic AI partnership can translate into concrete, late-stage clinical successes. Until then, the company remains in a high-stakes race against time, patent expirations, and a competitor in Eli Lilly that has shown no signs of slowing down.
About the Author
